18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.

Akira ToriiharaHeying DuanHolly M ThompsonSonya ParkNegin HatamiLucia BarattoAlice C FanAndrei H Iagaru

Published in: European journal of nuclear medicine and molecular imaging (2019)

18F-FPPRGD2 PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.

Keyphrases

pet ct
papillary thyroid
cell therapy
positron emission tomography
single cell
squamous cell
stem cells
squamous cell carcinoma
mesenchymal stem cells